Form 4: Natera CFO Michael Brophy Reports Stock Sales Under 10b5-1 Trading Plan

Natera's CFO, Michael Brophy, executed multiple sales of common stock between April 24 and April 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Brophy, the Chief Financial Officer of Natera, Inc., reported the sale of Natera common stock.
• The transactions occurred between April 24 and April 26, 2024.
• A total of 937 shares were sold on April 24 at a price of $92.9991 per share.
• On April 25, 705 shares were sold at $89.55 per share.
• Finally, 751 shares were sold on April 26 at $92 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 14, 2023.
• Following these transactions, Brophy directly owns 70,646 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to insider stock sales under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales are under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any forward-looking statements.

Industry Context

Insider trading activity is always closely watched in the biotech industry, as it can provide signals about management's confidence in the company's future prospects. However, pre-planned sales under 10b5-1 plans are common and often unrelated to short-term expectations.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates